Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
LifeMD (NASDAQ: LFMD) announced a partnership with Particle Health to enhance personalized medical care through improved access to patient health records. With access to a database covering over 90% of the U.S. population, licensed providers can leverage comprehensive health data, paving the way for better healthcare outcomes. This strategic alliance aims to simplify healthcare delivery and strengthen patient-provider relationships, ultimately driving the launch of LifeMD's primary care platform.
LifeMD, Inc. (NASDAQ: LFMD) announced a conference call to discuss its second quarter fiscal 2021 financial results on August 12, 2021, at 4:30 p.m. ET. The results will be released prior to the call, and management will host the discussion followed by a Q&A session. LifeMD offers direct-to-patient telehealth services and products nationwide. The call can be accessed via toll-free and international dial-in numbers or streamed online. Interested parties should review the company's SEC filings for risk factors and historical financial data.
LifeMD (NASDAQ: LFMD) has partnered with Axle Health to provide telehealth access to over 150 diagnostic laboratory tests at preferred prices. Patients can complete tests securely in their homes or via local lab service centers. The collaboration aims to transform healthcare delivery by enhancing access to early diagnosis, which is crucial for effective healthcare outcomes. This integration is expected to improve patient services while supporting LifeMD's expansion in virtual primary care offerings.
On June 11, 2021, LifeMD, Inc. (NASDAQ: LFMD) appointed Alexander Mironov as President. Mironov brings over 20 years of experience in business development and M&A in the pharmaceutical sector, with transactions worth over $5 billion. His previous role at Covis Pharma saw revenue growth exceeding 10x. Mironov aims to transform LifeMD's telehealth services. He received options for 200,000 shares at $14.04, vesting over 36 months, plus a performance-based grant of 300,000 restricted shares based on deal contributions.
LifeMD, Inc. (NASDAQ: LFMD) successfully closed a $15 million debt financing with B. Riley Principal Investments, enhancing liquidity and supporting growth in its telehealth business. This marks LifeMD’s first debt financing and strengthens its balance sheet, aligning with its aggressive growth strategy through 2022. CFO Marc Benathen emphasized that the transaction validates LifeMD’s telehealth platform and enables further investment towards profitability. B. Riley views LifeMD as a promising investment, committing to leverage their banking platform for the company’s growth.
LifeMD (NASDAQ: LFMD) has announced its participation in two upcoming conferences: the Capital Peak Advisors Best Ideas Conference on June 2, 2021, at 11:00 am ET and the 2021 LD Micro Invitational XI on June 8, 2021, at 4:30 pm ET. The presentations will include 1x1 meetings for deeper engagement with participants. LifeMD is a direct-to-patient telehealth company offering virtual medical treatment and prescription services across the U.S. For more details, visit LifeMD.com.
LifeMD, Inc. (NASDAQ: LFMD) has announced the voluntary dismissal of two shareholder lawsuits filed against the company, which were considered meritless. The cases, Owens v. LifeMD and Cho v. LifeMD, were filed in the U.S. District Court for the Southern District of New York and formally dismissed on May 18 and 19, 2021. LifeMD remains committed to enhancing access to healthcare through its telemedicine platform. The company emphasizes a focus on transparency, integrity, and patient care.
LifeMD announces the appointment of Dr. Matthew Zipoli as a medical advisor for its tele-dermatology brand, Nava MD. Dr. Zipoli, a leading dermatologist with over 20 years of experience in Mohs Surgery, aims to enhance the brand's development goals. His affiliation with reputable hospitals and teaching credentials at Tufts University School of Medicine underscore his expertise. Chief Medical Officer Dr. Anthony Puopolo emphasizes the expected growth in subscriber base and brand recognition for Nava MD as they optimize their tele-dermatology offerings.
LifeMD (NASDAQ: LFMD) has announced partnerships with actresses Kate del Castillo and Bellamy Young to promote its Shapiro MD™ hair loss treatment solutions. These campaigns aim to reach a broad audience through online and offline advertising, as both actresses share their personal experiences with Shapiro MD's products. Dr. Anthony Puopolo, LifeMD's Chief Medical Officer, noted that hair loss affects over 50% of the population. The partnerships will leverage the significant social media followings of both actresses.
On May 17, 2021, LifeMD, Inc. (NASDAQ: LFMD) announced the granting of an equity award to a new employee as an inducement for their hiring. The award comprises options to purchase 75,000 shares at an exercise price of $7.73, matching the stock's closing price on the grant date. Vesting occurs in three equal annual installments over three years, contingent on continued employment. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4) and is outside the company's 2020 Equity and Incentive Plan.